Symbols

ARQT

Arcutis·NASDAQ

--(--)

ARQT fundamentals

ARQT Q4 2025 Earnings

Arcutis (ARQT) released its earnings on Feb 25, 2026: revenue was 129.50M (YoY +81.48%), beat estimates; EPS was 0.13 (YoY +244.44%), beat estimates.

Revenue / YoY

129.50M

+81.48%

EPS / YoY

0.13

+244.44%

Report date

Feb 25, 2026

ARQT Earnings Call Summary for Q4,2025

Revenue Surge: Q4 2025 revenue $127.5M (+84% YoY), full year $372.1M (+123% YoY). 2026 guidance raised to $480-495M.
ZORYVE Expansion: 5 new FDA approvals, 45% market share of branded nonsteroidals. 2026 pipeline includes 3-24mo AD sNDA and 2-5y/o psoriasis PDUFA.
Financial Health: Positive cash flow ($26.2M Q4), $221M cash, no gross-to-net erosion.
Clinical Momentum: 58% EASI-75 in 2-5y/o AD, ARQ-234 Phase I start. HS and vitiligo trials advancing.
Strategic Moves: 20% sales force expansion, internal primary care team, $100M undrawn revolver.

Earnings

EPS

Revenue

Revenue & Expenses

ARQT has released its 2025 Q4 earnings report, with revenue of 129.50M, reflecting a YoY change of 81.48%, and net profit of 17.39M, showing a YoY change of 261.24%. The Sankey diagram below clearly presents ARQT's revenue sources and cost distribution.

Key Indicators

Arcutis (ARQT) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Arcutis (ARQT)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Arcutis (ARQT)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Arcutis (ARQT)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown